PharmaCyte Biotech, Inc. (PMCB)
NASDAQ: PMCB · Real-Time Price · USD
0.4208
-0.0202 (-4.58%)
Sep 28, 2026, 10:17 AM EDT - Market open
PharmaCyte Biotech Balance Sheet
Financials in millions USD. Fiscal year is May - April.
Millions USD. Fiscal year is May - Apr.
Assets
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Apr '26 Apr 30, 2026 | Apr '25 Apr 30, 2025 | Apr '24 Apr 30, 2024 | Apr '23 Apr 30, 2023 | Apr '22 Apr 30, 2022 |
Cash & Equivalents | 17.74 | 18.6 | 15.17 | 50.18 | 68.04 | 85.4 |
Short-Term Investments | 12.77 | 18.48 | 0.37 | - | - | - |
Cash & Short-Term Investments | 30.51 | 37.08 | 15.54 | 50.18 | 68.04 | 85.4 |
Cash Growth | 127.03% | 138.65% | -69.03% | -26.25% | -20.33% | 3778.14% |
Other Receivables | 0.43 | 0.24 | - | - | - | - |
Receivables | 0.43 | 0.24 | 3.7 | - | - | - |
Prepaid Expenses | 0.03 | 0.1 | 0.22 | 0.26 | 0.11 | 0.09 |
Other Current Assets | - | - | 2.92 | - | - | - |
Total Current Assets | 30.97 | 37.42 | 22.38 | 50.44 | 68.15 | 85.49 |
Long-Term Investments | - | - | 22.47 | - | 1.57 | 1.57 |
Other Intangible Assets | - | - | 1.55 | 1.55 | 3.55 | 3.55 |
Other Long-Term Assets | 5.74 | 9.33 | 8.77 | 7.91 | 0.01 | 0.01 |
Total Assets | 36.71 | 46.75 | 55.17 | 59.9 | 73.28 | 90.62 |
Liabilities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Apr '26 Apr 30, 2026 | Apr '25 Apr 30, 2025 | Apr '24 Apr 30, 2024 | Apr '23 Apr 30, 2023 | Apr '22 Apr 30, 2022 |
Accounts Payable | 0.39 | 0.27 | 0.4 | 0.39 | 0.13 | 0.21 |
Accrued Expenses | 0.35 | 0.5 | 0.52 | 0.74 | 0.46 | 0.5 |
Other Current Liabilities | 0.03 | 0.06 | 1.99 | 6.3 | - | - |
Total Current Liabilities | 0.77 | 0.83 | 2.91 | 7.42 | 0.59 | 0.7 |
Other Long-Term Liabilities | 6.13 | 10.95 | 0.36 | 12.97 | - | - |
Total Liabilities | 6.9 | 11.77 | 3.28 | 20.39 | 0.59 | 0.7 |
Shareholders' Equity
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Apr '26 Apr 30, 2026 | Apr '25 Apr 30, 2025 | Apr '24 Apr 30, 2024 | Apr '23 Apr 30, 2023 | Apr '22 Apr 30, 2022 |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Additional Paid-In Capital | 182.01 | 182.72 | 181.49 | 185.33 | 202.23 | 201.58 |
Retained Earnings | -109.47 | -104.39 | -84.97 | -115.63 | -115.96 | -111.65 |
Treasury Stock | -45.01 | -45.01 | -44.61 | -42.04 | -13.56 | - |
Comprehensive Income & Other | 0.4 | 0.4 | -0.02 | -0.02 | -0.02 | -0.02 |
Total Common Equity | 27.93 | 33.71 | 51.89 | 27.65 | 72.69 | 89.92 |
Shareholders' Equity | 29.82 | 34.98 | 51.89 | 39.51 | 72.69 | 89.92 |
Total Liabilities & Equity | 36.71 | 46.75 | 55.17 | 59.9 | 73.28 | 90.62 |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Apr '26 Apr 30, 2026 | Apr '25 Apr 30, 2025 | Apr '24 Apr 30, 2024 | Apr '23 Apr 30, 2023 | Apr '22 Apr 30, 2022 |
Net Cash (Debt) | 30.51 | 37.08 | 15.54 | 50.18 | 68.04 | 85.4 |
Net Cash Growth | 127.03% | 138.65% | -69.03% | -26.25% | -20.33% | 3869.72% |
Net Cash Per Share | 3.26 | 4.43 | 2.12 | 5.24 | 3.49 | 5.50 |
Filing Date Shares Outstanding | 10.74 | 10.74 | 6.8 | 7.71 | 8.78 | 20.75 |
Total Common Shares Outstanding | 10.74 | 10.74 | 6.8 | 8.04 | 16.79 | 20.72 |
Working Capital | 30.21 | 36.59 | 19.46 | 43.02 | 67.56 | 84.79 |
Book Value Per Share | 2.60 | 3.14 | 7.64 | 3.44 | 4.33 | 4.34 |
Tangible Book Value | 27.93 | 33.71 | 50.34 | 26.1 | 69.14 | 86.37 |
Tangible Book Value Per Share | 2.60 | 3.14 | 7.41 | 3.25 | 4.12 | 4.17 |